''For further information see: [[Phenothiazine]]''

 


 
Thioridazine prolongs the [[QT interval|QTc interval]] in a dose-dependent manner.<ref name = DM>{{cite web|title=THIORIDAZINE HYDROCHLORIDE tablet, film coated [Mutual Pharmaceutical]|work=DailyMed|publisher=Mutual Pharmaceutical|date=September 2010|accessdate=28 October 2013|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c4bedb4-2d59-4fcd-aad7-fce988cd96d8}}</ref> It produces significantly less [[extrapyramidal side effects]] than most first-generation antipsychotics.<ref>{{cite journal|title=Thioridazine for schizophrenia|journal=The Cochrane Database of Systematic Reviews|date=July 2007|issue=3|pages=CD001944|doi=10.1002/14651858.CD001944.pub2|pmid=17636691|author1=Fenton, M |author2=Rathbone, J |author3=Reilly, J |author4=Sultana, A |url=http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001944.pub2/pdf}}</ref><ref>{{cite journal|title=The Australian multicentre double-blind comparative study of remoxipride and thioridazine in schizophrenia|journal=Acta Psychiatrica Scandinavica|volume=90|issue=5|date=November 1994|pages=358–365|doi=10.1111/j.1600-0447.1994.tb01607.x|pmid=7872041|author1=Keks, N |author2=McGrath, J |author3=Lambert, T |author4=Catts, S |author5=Vaddadi, K |author6=Burrows, G |author7=Varghese, F |author8=George, T |author9=Hustig, H |author10=Burnett, P |display-authors=etal}}</ref> Its use, along with the use of other typical antipsychotics, has been associated with degenerative retinopathies.<ref>{{cite journal|title=Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis|journal=Documenta Ophthalmologica|date=July 2002|volume=105|issue=1|pages=41–49|doi=10.1023/A:1015768114192|pmid=12152801|author1=Fornaro, P |author2=Calabria, G |author3=Corallo, G |author4=Picotti, GB |url=https://link.springer.com/article/10.1023%2FA%3A1015768114192}}</ref> It has a higher propensity for causing [[anticholinergic]] side effects coupled with a lower propensity for causing [[extrapyramidal side effects]] and sedation than [[chlorpromazine]], but also has a higher incidence of hypotension and cardiotoxicity.<ref>{{cite web|title=Martindale: The Complete Drug Reference|date=18 August 2010|accessdate=28 October 2013|work=Medicines Complete|publisher=The Pharmaceutical Press|url=https://www.medicinescomplete.com/mc/martindale/current/login.htm?uri=http%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2Fcurrent%2F}}</ref> It is also known to possess a relatively high liability for causing [[orthostatic hypotension]] compared to other antipsychotics. Similarly to other first-generation antipsychotics it has a relatively high liability for causing prolactin elevation. It is moderate risk for causing weight gain.<ref name = UpToDate>{{cite web|title=Selected adverse effects of antipsychotic medications for schizophrenia|work=UpToDate|publisher=Wolters Kluwer Health|accessdate=24 October 2013|url=http://www.uptodate.com/contents/pharmacotherapy-for-schizophrenia-side-effect-management?detectedLanguage=en&source=search_result&search=Selected+adverse+effects+of+antipsychotic+medications+for+schizophrenia&selectedTitle=1%7E150&provider=noProvider#subscribeMessage}}</ref> As with all antipsychotics thioridazine has been linked to cases of [[tardive dyskinesia]] (an often permanent neurological disorder characterised by slow, repetitive, purposeless and involuntary movements, most often of the facial muscles, that is usually brought on by years of continued treatment with antipsychotics, especially the first-generation (or ''typical'') antipsychotics such as thioridazine) and [[neuroleptic malignant syndrome]] (a potentially fatal complication of antipsychotic treatment).<ref name = DM/> Blood dyscrasias such as [[agranulocytosis]], [[leukopenia]] and [[neutropenia]] are possible with thioridazine treatment.<ref name = DM/>

 

